CAM Group Holding A S continued to hold its stake in Relypsa Inc. (NASDAQ:RLYP) during the second quarter, Holdings Channel reports. The institutional investor owned 268,000 shares of the company’s stock at the end of the second quarter. CAM Group Holding A S’s holdings in Relypsa were worth $4,958,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in RLYP. Capital Fund Management S.A. acquired a new stake in Relypsa during the second quarter worth about $371,000. Jacobs Levy Equity Management Inc. acquired a new stake in Relypsa during the first quarter worth about $637,000. Rice Hall James & Associates LLC boosted its stake in Relypsa by 1.3% in the second quarter. Rice Hall James & Associates LLC now owns 132,850 shares of the company’s stock worth $2,458,000 after buying an additional 1,676 shares during the last quarter. Scopia Capital Management LP acquired a new stake in Relypsa during the first quarter worth about $4,930,000. Finally, JPMorgan Chase & Co. boosted its stake in Relypsa by 1.2% in the first quarter. JPMorgan Chase & Co. now owns 378,047 shares of the company’s stock worth $5,123,000 after buying an additional 4,419 shares during the last quarter.
Shares of Relypsa Inc. (NASDAQ:RLYP) remained flat at $31.99 during trading on Tuesday. The firm’s 50 day moving average price is $30.31 and its 200 day moving average price is $20.28. Relypsa Inc. has a 12 month low of $10.26 and a 12 month high of $32.12.
Relypsa (NASDAQ:RLYP) last announced its earnings results on Thursday, August 4th. The company reported ($1.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by $0.31. The firm earned $5.22 million during the quarter, compared to analysts’ expectations of $5.45 million. Equities research analysts expect that Relypsa Inc. will post ($6.33) earnings per share for the current year.
RLYP has been the subject of a number of recent analyst reports. Brean Capital reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Relypsa in a research report on Monday, July 18th. Stifel Nicolaus reiterated a “buy” rating and set a $36.00 target price on shares of Relypsa in a research note on Friday, July 15th. BTIG Research reiterated a “buy” rating and set a $35.00 target price on shares of Relypsa in a research note on Friday, July 15th. Cantor Fitzgerald set a $41.00 target price on Relypsa and gave the stock a “buy” rating in a research note on Thursday, July 21st. Finally, Vetr lowered Relypsa from a “strong-buy” rating to a “buy” rating and set a $34.01 target price on the stock. in a research note on Wednesday, August 24th. Twelve investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Relypsa presently has a consensus rating of “Hold” and a consensus target price of $35.87.
In other news, major shareholder James D. Dondero sold 37,000 shares of the business’s stock in a transaction that occurred on Thursday, August 11th. The stock was sold at an average price of $31.96, for a total value of $1,182,520.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Orbimed Advisors Llc sold 4,043,600 shares of the business’s stock in a transaction that occurred on Monday, July 25th. The stock was sold at an average price of $32.00, for a total value of $129,395,200.00. The disclosure for this sale can be found here.
Relypsa, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients’ lives and even be life-threatening. The Company’s first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia.
Want to see what other hedge funds are holding RLYP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Relypsa Inc. (NASDAQ:RLYP).
Receive News & Ratings for Relypsa Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc. and related companies with MarketBeat.com's FREE daily email newsletter.